Immunocytochemistry and fluorescence in situ hybridization in HER-2/neu status in cell block preparations

Acta Cytologica

Volumn 51, Issue 4, 2007, Pages 552-557

  Shin, Sandra J ^a   Chen, Beiyun ^b   Hyjek, Elizabeth ^a   Vazquez, Madeline ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cell block; Fluorescence in situ hybridization; HER 2 neu; Immunocytochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB11; MONOCLONAL ANTIBODY TAB250; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHEMISTRY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; VALIDATION PROCESS;

EID: 34547096241     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000325793     Document Type: Article

References (26)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
2. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1997;34:791-808
3. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbaghazen R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Bettelheim R, Neville AM, Bürk K, Castiglione M, Collins J, Lindtnerj, Senn H-J: Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056
4. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266
5. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220-1226
6. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Omerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593-600
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eirmann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
8. Baselga J, Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol Suppl 1 2001;12:S35-S41
9. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-1769
10. Masood S, Bui MM: Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30:259-265
11. Gancberg D, DiLeo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:993-994
12. Lear-Kaul KC, Yoon H-R, Kleinschmidt-DeMasters BK, McGavran L, Singh M: HER-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003;127:1451-1457
13. Nizzoli R, Bozzetti C, Crafa P, Naldi N, Guazzi A, Di Blasio B, Camisa R, Cascinu S: Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol 2003;28:142-146
14. Troncone G, Panico L, Vetrani A, De Divitiis B, Zeppa P, Fulciniti F, Pettenato G, Palombini L: C-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol 1996;14:135-139
15. Klorin G, Keren R: Prognostic markers in histologic and cytologic specimens of breast cancer. Anal Quant Cytol Histol 2003;5:297-302
16. Jorda M, Ganjei P, Nadji M: Retrospective c-erbB-2 immunostaining in aspiration cytology of breast cancer. Diagn Cytopathol 1993;11:262-265
17. Corkill ME, Katz R: Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1993;11:250-254
18. Solomides CC, Zimmerman R, Bibbo M: Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma. Analyt Quant Cytol Histol 1999;21:121-125
19. Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, Nalda N, Cascinu S: HER-2/neu amplification detected by fluorescence in-situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 2002;13:1398-1403
20. Moore JG, To V, Patel S, Sneige N: HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: Direct comparison with companion tissue sections. Diagn Cytopathol 2000;23:299-302
21. Beauty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, Weaver DL: HER-2/neu detection in fine-needle aspirates of breast cancer: Fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 2004;122: 246-255
22. Sneige N: Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: Current issues and future directions. Diagn Cytopathol 2004;30:158-165
23. Schnitt SJ, Jacobs TW: Current status of HER2 testing. Am J Clin Pathol 2001;116:806-810
24. Cobleigh M, Vogel C, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lierberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
25. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML: HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival. Mol Diagn 2000;5:199-207
26. Mass RD, Press MF, Anderson S, Murphy M, Slamon D: Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) (abstr). Proc Oncol 2001;20:22a